Medidata, a leading global provider of cloud-based solutions for clinical research in life sciences, announced this week that it is collaborating with Memorial Sloan Kettering Cancer Center (MSK) to expand the use of mobile health (mHealth) technology in oncology treatment.
Through the collaboration, we’re told, Medidata and MSK “will assess the viability of deploying wearable sensors and mobile technology to evaluate quality of life during cancer treatment.”
MSK says it will use activity trackers, mobile apps and Medidata’s cloud technology platform to study patterns of movement in patients being treated for multiple myeloma.
“In the wake of the president’s Cancer Moonshot, there is a renewed urgency to combine the best science with the best technology to deliver better treatments faster,” said Medidata’s president Glen de Vries. “Success in cancer treatment is measured not just by what it does to the disease but what it does to the patient’s body and mind. Our collaboration with MSK will bring to bear the very best technology and data analytics to help researchers identify multiple myeloma treatments that best enhance quality as well as quantity of life.”